In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Perspective Therapeutics (CATX – Research Report). The company’s shares closed yesterday at $6.96. Don't Miss our ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $74.00. The ...

Fintel reports that on November 18, 2024, RBC Capital initiated coverage of TechnipFMC (NYSE:FTI) with a Outperform ...

Stock futures hovered near the flatline on Tuesday evening, as investors looked toward a key earnings report from tech giant ...

RBC Capital analyst Manjari Dhar initiated coverage of J Sainsbury (JSAIY) with an Outperform rating and 300 GBp price target ...

Tariffs have taken the spotlight as a policy issue as S&P 500 companies have discussed earnings with analysts since the U.S.

Michael Reid, the US Economist at RBC Capital Markets, says the Fed is still on track for a rate cut in December.

Rathbones Asset Management has expanded its multi-asset team with the hire of equity research analyst Emma Letheren.

Shares of Imperial Brands (LON: IMB) rose on Tuesday after the tobacco and next-generation products (NGP) company posted ...

RBC Capital raised its price target for Tesla (NASDAQ: TSLA) to $387 from $323 in a note Friday, citing growing confidence in ...

On Friday, CoStar Group Inc (CSGP) stock saw a decline, ending the day at $71.25 which represents a decrease of $-3.79 or -5.05% from the prior close of $75.04. The stock opened at $74.96 and touched ...

How our approach to investing can inform your stock-picking process. We sell different types of products and services to both investment professionals and individual investors. These products and ...